A Phase I Clinical Trial of Topotecan Given Every 2 Weeks in Patients with Refractory Solid Tumors

Publisher： Karger

E-ISSN： 1423-0232|61|4|265-270

ISSN： 0030-2414

Source： Oncology, Vol.61, Iss.4, 2001-11, pp. : 265-270

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase 1 clinical trial of sequential pralatrexate followed by a 48‐hour infusion of 5‐fluorouracil given every other week in adult patients with solid tumors

By  

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3862-3868

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I Study of Paclitaxel (Taxol) and Pegylated Liposomal Doxorubicin (Caelyx) Administered Every 2 Weeks in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 62, Iss. 3, 2002-06 ,pp. : 216-222

Karger

Access to resources Recommend Favorite

Phase I Clinical Trial of a Day-1, -3, -5 Every 3 WeeksPhase I Clinical Trial of Day-1, -3, -5 Every 3 Weeks Schedule with Titanocene Dichloride (MKT 5) in Patients with Advanced Cancer. (Phase I Study Group of the AIO of the German Cancer Society)

By  

Oncology Research and Treatment, Vol. 23, Iss. 6, 2001-01 ,pp. : 576-579

Karger

Access to resources Recommend Favorite

Topotecan, Ara-C, Cisplatin and Prednisolone (TOPOSHAP) for Patients with Refractory and Relapsing Lymphomas: Results of a Phase I Trial

By  

Acta Haematologica, Vol. 112, Iss. 3, 2004-09 ,pp. : 121-125

Karger

Access to resources Recommend Favorite

Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 9, 2015-09 ,pp. : 1562-1566

John Wiley & Sons Inc

Access to resources Recommend Favorite